Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE vs AMINOSYN 10% (PH6)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral or enteral nutrition is impossible or insufficient
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
The terminal elimination half-life of individual amino acids varies (1–4 hours) depending on metabolic demand and renal function. For the amino acid mixture, the effective half-life is approximately 2 hours in patients with normal renal function. This short half-life necessitates continuous or frequent infusion to maintain stable plasma levels.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Amino acids are metabolized through deamination, transamination, and decarboxylation pathways, primarily in the liver, with nitrogen converted to urea via the urea cycle and carbon skeletons entering the Krebs cycle.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids from Aminosyn 10% are primarily utilized for protein synthesis and metabolic processes. Excess nitrogen is eliminated via the kidneys as urea (renal elimination accounts for >90% of nitrogen excretion). Minimal biliary/fecal elimination (<5%) occurs via unabsorbed amino acids in patients with malabsorption. In renal impairment, elimination is reduced.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Amino acids exhibit low protein binding (<10%) to plasma proteins (primarily albumin). High-affinity binding is negligible; most amino acids circulate freely.
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Volume of distribution (Vd) for amino acids in Aminosyn 10% ranges from 0.3–0.5 L/kg, approximating total body water. This reflects extensive distribution into extracellular and intracellular compartments.
Intravenous: 100%.
Bioavailability is 100% when administered intravenously. Not applicable for oral, intramuscular, or other routes; Aminosyn 10% is for IV use only.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
For GFR 30-59 m L/min: reduce dose to 0.8-1.0 g/kg/day. For GFR 15-29 m L/min: 0.6-0.8 g/kg/day. For GFR <15 m L/min or dialysis: 0.5-0.6 g/kg/day; monitor for azotemia.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 30-50% and use a formulation with higher branched-chain amino acids. Child-Pugh Class C: avoid or use with extreme caution, adjust based on ammonia levels.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Infants (0-1 year): 2-3 g/kg/day (20-30 m L/kg/day). Children (1-12 years): 1.5-2.5 g/kg/day (15-25 m L/kg/day). Adolescents: 1-1.5 g/kg/day (10-15 m L/kg/day). Administer as continuous IV infusion.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
Initiate at lower end of dosing range (0.8-1 g/kg/day) due to reduced renal function and increased risk of fluid overload; monitor serum electrolytes and renal function closely.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
None
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Risk of hyperammonemia, especially in patients with hepatic impairment,Risk of metabolic acidosis,Risk of fluid overload and electrolyte imbalances,Monitor for signs of infection or phlebitis at infusion site,Use with caution in patients with renal insufficiency as may worsen azotemia
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease),Severe hepatic failure with encephalopathy,Severe azotemia or anuria
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
No specific food interactions. However, since this is used in parenteral nutrition, oral intake may be contraindicated. Adjustments may be needed if transitioning to oral feeding.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studies. First trimester: No evidence of fetal harm. Second/third trimester: Use only if clearly needed; monitor maternal and fetal status.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Excretion of amino acids into breast milk is not well studied. Considering the endogenous nature of amino acids, risk to infant is likely low if used at recommended doses. M/P ratio not determined.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
No specific dose adjustments required. Pregnancy may alter fluid and electrolyte needs; individualize dosing based on clinical status and laboratory parameters.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
Aminosyn 10% (p H 6) is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, BUN, and ammonia levels due to risk of metabolic abnormalities. Adjust infusion rate to avoid hyperglycemia or hypoglycemia. Use with caution in renal or hepatic impairment. Check for compatible additives and avoid mixing with lipids in the same container unless validated.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
Report any signs of infection at the IV site, such as redness, swelling, or pain.,Inform your healthcare provider if you experience nausea, vomiting, or dizziness.,This solution provides essential nutrients; do not stop treatment without consulting your doctor.,Keep an eye on your blood sugar levels if you have diabetes.,Do not take any other nutritional supplements without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE vs AMINOSYN 10% (PH6), answered by our medical review team.
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. AMINOSYN 10% (PH6) is a Parenteral Nutrition Solution that works by Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE and AMINOSYN 10% (PH6) depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. The standard adult dose of AMINOSYN 10% (PH6) is: Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE and AMINOSYN 10% (PH6) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. AMINOSYN 10% (PH6) is classified as Category C. Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.